Major depressive disorder is a chronic and debilitating disease characterized by a wide range of emotional and physical symptoms that coexist during a depressive episode and may reoccur at some point during the progression of the disease for the majority of patients. The purpose of the study was to investigate psychiatrists' experience regarding the response to antidepressive treatment and their options regarding augmentation strategies in depression with incomplete response to antidepressant monotherapy. Method: We applied an 18-item questionnaire containing multiple choice questions to adult psychiatrists working in ambulatories, hospitals or mental health centers. Results: Fourty-two psychiatrists have agreed to answer the questionnaire. The majority of them were psychiatry specialists, between 35 and 49 years of age, working in an outpatient unit. For the majority of doctors, SSRIs (Serotonin Reuptake Inhibitors) proved to be the fi rst line treatment both for the fi rst depressive episode and for recurrent depression, followed by SNRI (Serotonin and Noradrenalin Reuptake Inhibitors). Regarding the duration of maintenance treatment for the patients who achieved complete remission after the fi rst episode of depression, the results showed a wide spectrum from 4 to 9 months. Conclusions: Incomplete response to antidepressive monotherapy is very frequent both for the fi rst depressive episode and for recurrent depression. Given the pharmacological profi le that some atypical antipsychotic have, augmentation with atypical antipsychotics in patients with inadequate response to antidepressant monotherapy is a useful therapeutic strategy that should be considered.
Introduction
Major Depressive Disorder (MDD) is a chronic and debilitating disease, characterized by a wide range of emotional and physical symptoms that can coexist during a depressive episode and may reoccur at some point in the evolution of the disease. It is considered that by 2020 depression will be the second leading cause of morbidity worldwide after cardiovascular disease. For patients with a major depressive episode, the possibility of experiencing another episode at some point in the future is 85% [1] . Remission rates after the fi rst antidepressant treatment are small (less than 30%) and incomplete or suboptimal response is frequently encountered [2] .
Strategies adopted for patients with incomplete response to antidepressant treatment may include: optimizing the dose, switching to another antidepressant, combinations of antidepressants, augmentation with carbamazepine, lithium, buspirone, thyroid hormones or an atypical antipsychotic, pharmacotherapy combined with psychotherapy, deprivation of sleep, light therapy, electroconvulsive therapy (ECT), vagus nerve stimulation, transcranial magnetic stimulation and deep brain stimulation [3, 4] .
Our study aims to assess the experience of psychiatrists about patients with incomplete response to antidepressant monotherapy.
Objectives
-Demonstration of increased frequency of incomplete response to antidepressant monotherapy; -Evidence that the SSRIs and SNRIs are the most commonly used classes of antidepressants as for the fi rst episode depression, recurrent depression; -Evidence that augmentation with atypical antipsychotics is the preferred method of psychiatrists compared to other treatment options for depression with incomplete response to antidepressant monotherapy.
Methods
Evaluation of therapeutic options of psychiatrists was based on a questionnaire with 18 items (presented at the end of this paper), designed by team members. Th e questionnaire comprises 18 multiple-choice questions addressed to specialized outpatient psychiatrists, hospitals or mental health centres. After general questions related to age, employment, vocational training and seniority, there is a set of questions about treatment options for the fi rst
Correspondence to: Theodor Moica E-mail: moica_dorel@yahoo.com depressive episode and for recurrent depressive episodes. Th e last question concerns the eff ectiveness of atypical antipsychotics used as augmentation therapy in depression, with incomplete response to antidepressant monotherapy. For the interpretation of data we used statistical programs SPSS 11 for Windows and GraphPad Prism version 6.
Results
Th e questionnaire was sent to 60 psychiatrists. Fourty-two of them have agreed to answer the questionnaire, all of them from Mureș county. Th e majority of the respondents were psychiatry specialists, between 35 and 49 years of age, working in an outpatient unit (Figure 1) .
Regarding the therapeutic option in the fi rst depressive episode as fi rst-line therapy, the responders could choose between the next seven options:
-SSRI -Serotonin Reuptake Inhibitors (paroxetinum, sertralinum, citalopramum, escitalopramum, fl uvoxaminum, fl uoxetinum); -SNRI -Serotonin and Noradrenalin Reuptake Inhibitors (venlafaxinum, duloxetinum, milnacipran); -AD Tricyclics (ampitriptilinum, clomipraminum, doxepinum); -NDRI -Norepinephrine-dopamine reuptake inhibitors (bupropion); -NaSSa -Noradrenergic and specifi c serotonergic antidepressants (mirtazapinum, mianserinum); -SARI -Serotonin antagonist and reuptake inhibitors (nefazodone, trazodone);
-Others: tianeptinum, agomelatinum. As shown in Figure 2 , for the majority of doctors, SSRIs (Serotonin Reuptake Inhibitors) proved to be the fi rst line treatment for the fi rst depressive episode, followed by SNRI (Serotonin and Noradrenalin Reuptake Inhibitors). No correlation was found between the age of responders and treatment preference.
Regarding the duration of maintenance treatment for the patients who achieved complete remission after the fi rst episode of depression, the results showed a wide spectrum from 4 to 9 months (Figure 3 ). On average, incomplete response to antidepressive monotherapy was reported to be 25% in case of fi rst depressive episode and 28% for recurrent depression.
As shown in Figure 4 , in case of incomplete response, psychiatrists used all available therapeutic strategies, with the mention that augmentation with atypical antipsychotics is the preferred method. Quetiapine, olanzapine and aripiprazole are considered to be the most eff ective atypical antipsychotics in this case.
Discussions
Incomplete response in depression is always associated with an increased risk of relapse [5, 6] , a signifi cant impairment in all functions (social, occupational, academic) [7] and an increase in costs associated with the treatment of these patients [8, 9] .
We need to fi nd new strategies in this case, taking into account the fact that with monotherapy only 1/3 of depressed patients achieve remission. If we think that in 2020 depres- sion will be the second cause of morbidity after cardiovascular diseases and the guides for the treatment of ischemic cardiopathy, for example, recommend at least 3 drugs from diff erent classes, it should not be a problem to recommend two classes of drugs for a depressed patient, although a large number of psychiatrists do not agree with this.
Our paper demonstrates that augmentation with atypical antipsychotics is the preferred method of augmentation for psychiatrists from Mureș county, compared to other treatment options for depression with incomplete response to antidepressant monotherapy. Th is is the case regardless if the neuroleptic is already approved or is being used off label. A meta-analysis made by Papakostas et al. in 2007 showed that the response to an antidepressant augmentation with an atypical antipsychotic may be benefi cial in patients with treatment-resistant depression [10] .
Studies over the past fi ve years have shown the benefi cial eff ect of combining atypical antipsychotics (e.g. aripiprazole or quetiapine), not only in the case of patients with resistant depression, but also in those cases where there is an inadequate response, incomplete to antidepressive monotherapy [11] [12] [13] [14] [15] . Currently in Romania only quetiapine is approved for the treatment of depression with incomplete response, as an augmentation strategy to antidepressive monotherapy.
Most drugs with antidepressive eff ect exercise their eff ect by inhibiting reuptake of one or more neuromediators: serotonin (5-HT), dopamine (DA), norepinephrine (NE), but also by their function of 5-HT 2A receptor antagonists or partial agonists of 5-HT 1A autoreceptors. Th ese are also common mechanisms of action for atypical antipsychotics [5] .
In the future, we wish to extend our study to the entire country, and also to carry out a comparing study between Romania, France and England regarding the psychiatrist's therapeutic options in depression.
Conclusions
Incomplete response to antidepressive monotherapy is very frequent both for the fi rst depressive episode and for recurrent depression. Given the pharmacological profi le that some atypical antipsychotic have, augmentation with atypical antipsychotics in patients with inadequate response to antidepressant monotherapy is a useful therapeutic strategy that should be considered. Since currently there is relatively little data in this area, further clinical studies are needed to assess the risk-benefi t of association of antidepressive medication and atypical antipsychotics for depressed patients without psychotic features.
